Table 5.
Clinical parameters with dapagliflozin in increased LDL-C and decreased LDL-C subgroup
| Increased LDL-C group (n = 20) | Decreased LDL-C group (n = 20) | p valuesb | p valuesc | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre treatment | Post treatment | % change | p valuesa | Pre treatment | Post treatment | % change | p valuesa | |||
| Age (years) | 51.6 ± 8.2 | 56.9 ± 7.8 | 0.047* | |||||||
| BW (kg) | 78.8 ± 14.3 | 76.8 ± 15.4 | −2.5 | 0.002* | 78.0 ± 14.7 | 75.5 ± 14.5 | −3.2 | 0.001* | 0.853 | 0.394 |
| AST (IU/L) | 36.1 ± 22.3 | 29.4 ± 15.9 | −18.6 | <0.001* | 32.7 ± 16.3 | 24.1 ± 7.7 | −26.3 | 0.002* | 0.596 | 0.622 |
| ALT (IU/L) | 52.5 ± 46.1 | 39.9 ± 31.9 | −24.0 | 0.032* | 40.4 ± 23.6 | 26.7 ± 11.7 | −33.9 | 0.030* | 0.312 | 0.874 |
| γGTP (IU/L) | 51.0 ± 40.5 | 50.3 ± 62.6 | −1.4 | 0.930 | 55.5 ± 46.5 | 34.0 ± 20.4 | −38.7 | 0.030* | 0.750 | 0.119 |
| BUN (mg/dL) | 14.1 ± 3.8 | 16.3 ± 4.3 | 15.6 | 0.013* | 15.1 ± 4.9 | 17.3 ± 5.8 | 14.6 | 0.010* | 0.470 | 0.996 |
| Cre (mg/dL) | 0.71 ± 0.15 | 0.72 ± 0.17 | 1.4 | 0.700 | 0.72 ± 0.19 | 0.77 ± 0.29 | 6.9 | 0.170 | 0.964 | 0.258 |
| eGFR (mL/min/1.73 m2) | 89.0 ± 18.8 | 88.0 ± 17.6 | −1.1 | 0.661 | 83.3 ± 18.1 | 81.7 ± 22.1 | −1.9 | 0.507 | 0.342 | 0.861 |
| FPG (mg/dL) | 152 ± 46 | 127 ± 27 | −16.4 | 0.006* | 138 ± 50.1 | 116 ± 21 | −15.9 | 0.040* | 0.382 | 0.815 |
| HbA1c (%) | 7.51 ± 1.1 | 6.92 ± 0.94 | −7.9 | 0.002* | 7.72 ± 1.1 | 6.81 ± 0.67 | −11.8 | <0.001* | 0.575 | 0.225 |
| CPR index | 2.77 ± 15.2 | 2.35 ± 1.28 | −15.2 | 0.008* | 2.82 ± 1.28 | 2.44 ± 1.82 | −13.4 | 0.243 | 0.922 | 0.486 |
| Adiponectin (ng/mL) | 5.5 ± 3.8 | 7.2 ± 5.4 | 30.9 | 0.002* | 6.5 ± 2.8 | 8.0 ± 2.6 | 23.1 | 0.001* | 0.383 | 0.675 |
Data are expressed as mean ± standard deviation or percent changes after the treatment. Clinical and laboratory parameters in the subgroup whose LDL-C was increased or decreased by dapagliflozin treatment were analyzed
BW body weight, AST aspartate aminotransferase, ALT alanine aminotransferase, γGTP γ-glutamyltranspeptidase, BUN blood urea nitrogen, Cre creatinine, FPG fasting plasma glucose, LDL-C low-density lipoprotein-cholesterol
ap values for the intragroup comparison (pre vs. post treatment values in each subgroup, * p < 0.05)
bp values for intergroup comparison (increased LDL-C vs. decreased LDL-C group in the pre treatment values, * p < 0.05)
cp values for intergroup comparison (increased LDL-C vs. decreased LDL-C group in the changes from pre to post treatment, * p < 0.05)